#Taiwan #Taipei #Foresee Pharmaceuticals #leuprolide mesylate #Casppian Study

Foresee Pharmaceuticals Completes Phase 3 Casppian Study

In an exciting development for pediatric endocrinology, Foresee Pharmaceuticals has successfully concluded its Casppian Phase 3 clinical trial. This marks a significant achievement for the company and offers promising news for children diagnosed with Central Precocious Puberty (CPP), a condition characterized by the premature onset of puberty.

The completion of the trial came with the announcement that the Last Patient Last Visit (LPLV) has been reached. This trial tested the investigational drug FP-001, a formulation of leuprolide mesylate, a GnRH agonist designed to suppress hormone production. Notably, the results have indicated that an impressive 94% of participants achieved serum luteinizing hormone (LH) suppression within the therapeutic threshold after a six-month dosing interval. This performance notably exceeded the initial success requirement of 80%, affirming the drug's efficacy in controlling CPP.

Central Precocious Puberty presents various challenges, including concerns around short stature and psychosocial effects. Timely intervention is crucial for children diagnosed with this condition, as untreated cases can lead to accelerated skeletal maturation and potentially impact their adult height. Current treatment regimens generally require frequent injections, creating a burden on both patients and their families.

The results from the Phase 3 study were statistically significant (P-value = 0.0005), underscoring the reliability of the findings. The follow-up data showed FP-001 not only met but exceeded expectations, solidifying its potential as a revolutionary treatment option. Unlike traditional methods which often require continuous monthly doses, FP-001 proposes a less frequent approach with a six-month injection - a game-changer for many families.

Foresee's Senior Vice President of Clinical Development, Dr. Bassem Elmankabadi, stated, *"The robust LH suppression rate we recorded over six months following a single injection underscores the effectiveness of our Stabilized Injectable Formulation technology. We are now preparing a comprehensive New Drug Application (NDA) to submit to the U.S. Food and Drug Administration (FDA) by the end of 2026, alongside filings to other global health authorities."

The company's Chief Medical Officer, Dr. Yisheng Lee, emphasized the dual significance of FP-001's efficacy and safety profile throughout the trial. No unexpected adverse events were reported, presenting a favorable safety landscape and ensuring that this treatment could represent a major shift in managing children’s health care regarding hormonal treatments.

With regulatory discussions already in place, Foresee Pharmaceuticals is keen on expediting the path to approval. The anticipated timeline for NDA submission involves finishing clinical study reports and statistical analyses within the year 2026.

Moreover, the findings from the Casppian study have been accepted for presentation at the Endocrine Society's ENDO 2026 conference, a pivotal opportunity to showcase these important advancements in pediatric medicine.

The successful completion of the Casppian trial encapsulates Foresee's commitment to ongoing R&D and reflects the extensive efforts geared towards improving treatment for children suffering from rare conditions like CPP. It not only opens the door for a new therapeutic avenue but also instills hope among patients and families awaiting better solutions.

As the company navigates through the approval process, the wider medical community and patients alike look forward to the potential introduction of FP-001 as a groundbreaking, once every six-month treatment for Central Precocious Puberty. The aim remains clear: to lessen the burden of frequent injections and enhance the overall quality of life for affected children globally.